Limits...
Prognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance.

Minarik J, Pika T, Bacovsky J, Petrova P, Langova K, Scudla V - ScientificWorldJournal (2012)

Bottom Line: The analysis revealed significant differences of all three parameters in comparison of active and remission phase MM.Within the comparison of active disease (newly diagnosed and relapsing), there was no significant difference.The levels of all three parameters behave accordingly with MM activity.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine III, Palacky University and University Hospital Olomouc, 775 20 Olomouc, Czech Republic.

ABSTRACT
Our aim was to compare serum levels of selected biological parameters in different phases of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) to determine their diagnostic and prognostic potential. A cohort of 234 individuals was assessed for serum levels of hepatocyte growth factor (HGF), syndecan-1/CD(138) (SYN), and osteopontin (OPN). The patients with MM (N = 156) were divided into 3 groups: at the time of diagnosis (N = 45), in relapse/progression (N = 56), and in remission (N = 50). The analysis revealed significant differences of all three parameters in comparison of active and remission phase MM. Moreover, the parameters in active myeloma were significantly higher than in MGUS. Within the comparison of active disease (newly diagnosed and relapsing), there was no significant difference. Similar results were in remission phase MM and MGUS. There was no relationship of pretreatment levels of the parameters to therapeutic response. We conclude that serum levels of HGF, OPN, and SYN correspond to the activity of MM and might become useful in differentiation of MGUS, asymptomatic MM, and overt/symptomatic form of MM. The levels of all three parameters behave accordingly with MM activity. Pretreatment measurement without the assessment of their kinetics, however, has no relationship to therapeutic response.

Show MeSH

Related in: MedlinePlus

Comparison of serum levels of syndecan-1 (SYN) in different phases of multiple myeloma and in monoclonal gammopathy of undetermined significance. Vertical axis: serum levels of syndecan-1 (SYN, ng/mL). Horizontal axis: (A) multiple myeloma at the time of diagnosis, (B) multiple myeloma (MM) in relapse/progression, (C) remission phase multiple myeloma, (D) monoclonal gammopathy of undetermined significance (MGUS). The differences between active phase MM (A versus B), and remission phase myeloma and MGUS (C and D) were not statistically different. Significant differences were found between MM at the time of diagnosis and remission phase myeloma (A versus C; M 103,25 versus 31,06 ng/mL, P < 0,0001), MM at the time of diagnosis and MGUS (A versus D; M 103,25 versus 28,0 ng/mL, P < 0,0001), MM in relapse/progression and remission phase MM (B versus C; M 58,0 versus 31,06 ng/mL, P < 0,0001), and MM in relapse/progression and MGUS (B versus D; M 58,0 versus 28,0 ng/mL, P < 0,0001).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3351092&req=5

fig2: Comparison of serum levels of syndecan-1 (SYN) in different phases of multiple myeloma and in monoclonal gammopathy of undetermined significance. Vertical axis: serum levels of syndecan-1 (SYN, ng/mL). Horizontal axis: (A) multiple myeloma at the time of diagnosis, (B) multiple myeloma (MM) in relapse/progression, (C) remission phase multiple myeloma, (D) monoclonal gammopathy of undetermined significance (MGUS). The differences between active phase MM (A versus B), and remission phase myeloma and MGUS (C and D) were not statistically different. Significant differences were found between MM at the time of diagnosis and remission phase myeloma (A versus C; M 103,25 versus 31,06 ng/mL, P < 0,0001), MM at the time of diagnosis and MGUS (A versus D; M 103,25 versus 28,0 ng/mL, P < 0,0001), MM in relapse/progression and remission phase MM (B versus C; M 58,0 versus 31,06 ng/mL, P < 0,0001), and MM in relapse/progression and MGUS (B versus D; M 58,0 versus 28,0 ng/mL, P < 0,0001).

Mentions: Assessment of serum levels of HGF revealed statistically significant differences between medians (M) in patients with MM at diagnosis and in remission (M 2001,0 versus 1049,0 pg/mL, P < 0,0001), and in patients with MM in relapse/progression and in remission (M 1370,0 versus 1049,0 pg/mL, P < 0,0001), whereas the difference in HGF levels between patients at the time of diagnosis and in relapse/progression was not statistically significant (P = 0,051), Figure 1. Similar results showed the analysis of OPN and SYN. Within the assessment of serum levels of SYN, statistically significant differences of the medians were between the disease at the time of diagnosis and in remission (M 103,25 versus 31,06 ng/mL, P < 0,0001), and in relapse/progression versus remission of MM (M 58,0 versus 31,06 ng/mL, P < 0,0001), whereas the difference between newly diagnosed and progressing MM was not significant, showing just a trend (P = 0,041), Figure 2. Serum levels of OPN were significantly different only between MM at the time of diagnosis and in remission (M 123,1 versus 66,55 ng/mL, P = 0,0003). The levels of OPN between MM in relapse/progression and in remission (M 74,975 versus 66,55 ng/mL), and between MM at the time of diagnosis and in relapse/progression (M 123,1 versus 74,975) were not statistically significant (P = 0,101), Figure 3.


Prognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance.

Minarik J, Pika T, Bacovsky J, Petrova P, Langova K, Scudla V - ScientificWorldJournal (2012)

Comparison of serum levels of syndecan-1 (SYN) in different phases of multiple myeloma and in monoclonal gammopathy of undetermined significance. Vertical axis: serum levels of syndecan-1 (SYN, ng/mL). Horizontal axis: (A) multiple myeloma at the time of diagnosis, (B) multiple myeloma (MM) in relapse/progression, (C) remission phase multiple myeloma, (D) monoclonal gammopathy of undetermined significance (MGUS). The differences between active phase MM (A versus B), and remission phase myeloma and MGUS (C and D) were not statistically different. Significant differences were found between MM at the time of diagnosis and remission phase myeloma (A versus C; M 103,25 versus 31,06 ng/mL, P < 0,0001), MM at the time of diagnosis and MGUS (A versus D; M 103,25 versus 28,0 ng/mL, P < 0,0001), MM in relapse/progression and remission phase MM (B versus C; M 58,0 versus 31,06 ng/mL, P < 0,0001), and MM in relapse/progression and MGUS (B versus D; M 58,0 versus 28,0 ng/mL, P < 0,0001).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3351092&req=5

fig2: Comparison of serum levels of syndecan-1 (SYN) in different phases of multiple myeloma and in monoclonal gammopathy of undetermined significance. Vertical axis: serum levels of syndecan-1 (SYN, ng/mL). Horizontal axis: (A) multiple myeloma at the time of diagnosis, (B) multiple myeloma (MM) in relapse/progression, (C) remission phase multiple myeloma, (D) monoclonal gammopathy of undetermined significance (MGUS). The differences between active phase MM (A versus B), and remission phase myeloma and MGUS (C and D) were not statistically different. Significant differences were found between MM at the time of diagnosis and remission phase myeloma (A versus C; M 103,25 versus 31,06 ng/mL, P < 0,0001), MM at the time of diagnosis and MGUS (A versus D; M 103,25 versus 28,0 ng/mL, P < 0,0001), MM in relapse/progression and remission phase MM (B versus C; M 58,0 versus 31,06 ng/mL, P < 0,0001), and MM in relapse/progression and MGUS (B versus D; M 58,0 versus 28,0 ng/mL, P < 0,0001).
Mentions: Assessment of serum levels of HGF revealed statistically significant differences between medians (M) in patients with MM at diagnosis and in remission (M 2001,0 versus 1049,0 pg/mL, P < 0,0001), and in patients with MM in relapse/progression and in remission (M 1370,0 versus 1049,0 pg/mL, P < 0,0001), whereas the difference in HGF levels between patients at the time of diagnosis and in relapse/progression was not statistically significant (P = 0,051), Figure 1. Similar results showed the analysis of OPN and SYN. Within the assessment of serum levels of SYN, statistically significant differences of the medians were between the disease at the time of diagnosis and in remission (M 103,25 versus 31,06 ng/mL, P < 0,0001), and in relapse/progression versus remission of MM (M 58,0 versus 31,06 ng/mL, P < 0,0001), whereas the difference between newly diagnosed and progressing MM was not significant, showing just a trend (P = 0,041), Figure 2. Serum levels of OPN were significantly different only between MM at the time of diagnosis and in remission (M 123,1 versus 66,55 ng/mL, P = 0,0003). The levels of OPN between MM in relapse/progression and in remission (M 74,975 versus 66,55 ng/mL), and between MM at the time of diagnosis and in relapse/progression (M 123,1 versus 74,975) were not statistically significant (P = 0,101), Figure 3.

Bottom Line: The analysis revealed significant differences of all three parameters in comparison of active and remission phase MM.Within the comparison of active disease (newly diagnosed and relapsing), there was no significant difference.The levels of all three parameters behave accordingly with MM activity.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine III, Palacky University and University Hospital Olomouc, 775 20 Olomouc, Czech Republic.

ABSTRACT
Our aim was to compare serum levels of selected biological parameters in different phases of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) to determine their diagnostic and prognostic potential. A cohort of 234 individuals was assessed for serum levels of hepatocyte growth factor (HGF), syndecan-1/CD(138) (SYN), and osteopontin (OPN). The patients with MM (N = 156) were divided into 3 groups: at the time of diagnosis (N = 45), in relapse/progression (N = 56), and in remission (N = 50). The analysis revealed significant differences of all three parameters in comparison of active and remission phase MM. Moreover, the parameters in active myeloma were significantly higher than in MGUS. Within the comparison of active disease (newly diagnosed and relapsing), there was no significant difference. Similar results were in remission phase MM and MGUS. There was no relationship of pretreatment levels of the parameters to therapeutic response. We conclude that serum levels of HGF, OPN, and SYN correspond to the activity of MM and might become useful in differentiation of MGUS, asymptomatic MM, and overt/symptomatic form of MM. The levels of all three parameters behave accordingly with MM activity. Pretreatment measurement without the assessment of their kinetics, however, has no relationship to therapeutic response.

Show MeSH
Related in: MedlinePlus